Rothschild Capital Partners Lowers stake in DexCom (DXCM)

DexCom (DXCM) : Rothschild Capital Partners reduced its stake in DexCom by 2.58% during the most recent quarter end. The investment management company now holds a total of 66,359 shares of DexCom which is valued at $5,883,389 after selling 1,758 shares in DexCom , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.DexCom makes up approximately 3.02% of Rothschild Capital Partners’s portfolio.

Other Hedge Funds, Including , Artemis Investment Management Llp sold out all of its stake in DXCM during the most recent quarter. The investment firm sold 43,304 shares of DXCM which is valued $3,839,333. Kanaly Trust Co sold out all of its stake in DXCM during the most recent quarter. The investment firm sold 69 shares of DXCM which is valued $6,064.Checchi Capital Advisers boosted its stake in DXCM in the latest quarter, The investment management firm added 13 additional shares and now holds a total of 296 shares of DexCom which is valued at $26,015. DexCom makes up approx 0.01% of Checchi Capital Advisers’s portfolio.Patten Patten Inctn boosted its stake in DXCM in the latest quarter, The investment management firm added 1,775 additional shares and now holds a total of 50,425 shares of DexCom which is valued at $3,977,020. DexCom makes up approx 0.54% of Patten Patten Inctn’s portfolio.

DexCom opened for trading at $90.33 and hit $92.39 on the upside on Friday, eventually ending the session at $92.23, with a gain of 2.98% or 2.67 points. The heightened volatility saw the trading volume jump to 8,82,846 shares. Company has a market cap of $7,695 M.

On the company’s financial health, DexCom reported $-0.23 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 27, 2016. Analyst had a consensus of $-0.21. The company had revenue of $116.20 million for the quarter, compared to analysts expectations of $110.93 million. The company’s revenue was up 59.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.